Intravenous Magnesium Sulfate in Severe Asthma
Yes, intravenous magnesium sulfate is indicated for adults with severe acute asthma that remains refractory after 1 hour of intensive conventional therapy with high-dose inhaled β2-agonists, systemic corticosteroids, and oxygen. 1, 2
When to Administer IV Magnesium Sulfate
Administer 2 grams of IV magnesium sulfate over 20 minutes when:
- FEV1 or peak expiratory flow remains <40% predicted after initial bronchodilator treatment 2, 3
- Life-threatening features are present (silent chest, cyanosis, exhaustion, confusion, bradycardia, hypotension, or PaCO2 ≥5-6 kPa) 1, 2
- The patient has received at least 1 hour of intensive standard therapy without adequate improvement 1, 2
Standard Therapy That Must Precede Magnesium
Before considering magnesium sulfate, ensure the patient has received:
- High-dose nebulized β2-agonists: Albuterol 5 mg (or salbutamol) nebulized every 20 minutes for three doses, or continuous nebulization at 10-15 mg/hour 1, 3
- Systemic corticosteroids: Methylprednisolone 125 mg IV or prednisolone 30-60 mg orally 1
- Oxygen therapy: Targeting SpO2 92-95%, even in patients with normal baseline oxygenation 1, 3
- Ipratropium bromide: 0.5 mg nebulized, particularly for life-threatening exacerbations 1
Mechanism and Evidence Base
Magnesium causes bronchial smooth muscle relaxation independent of serum magnesium levels, providing a complementary bronchodilator effect to β-agonists 1, 2. A Cochrane meta-analysis of 7 studies demonstrated that IV magnesium sulfate improves pulmonary function and reduces hospital admissions, with the greatest benefit in patients with the most severe exacerbations 1, 2. The evidence shows moderate improvement in FEV1 and approximately 7 fewer hospital admissions per 100 patients treated 2.
Dosing and Administration
- Standard adult dose: 2 grams IV administered over 20 minutes 1, 2
- Infusion rate is critical: Administering faster than 20 minutes significantly increases risk of hypotension, flushing, and bradycardia 4, 2
- Do not delay for serum magnesium levels: The bronchodilator effect operates independently of baseline magnesium concentrations 4
Safety Profile and Monitoring
IV magnesium sulfate has a favorable safety profile with only minor side effects:
- Common: Flushing and light-headedness 1, 2
- Rare but serious: Hypotension and bradycardia if infused too rapidly 4
- Monitor blood pressure and heart rate during infusion 4
- Have calcium chloride available to reverse potential magnesium toxicity if needed 4
Important Clinical Caveats
Magnesium is an adjunct, not a replacement: Continue aggressive standard therapy including continuous nebulized β-agonists, high-dose corticosteroids, oxygen, and ipratropium 2, 3. The 1993 British Thoracic Society guidelines 1 do not mention magnesium sulfate, but this reflects the older evidence base; the 2010 American Heart Association guidelines 1 and multiple subsequent guidelines 4, 2 strongly support its use based on more recent meta-analyses.
Nebulized magnesium is less effective: While inhaled magnesium sulfate has been studied, it is significantly less effective than IV administration and should not be used as first-line adjunctive therapy 2, 5, 6. One small study showed benefit with nebulized magnesium 6, but the evidence for IV administration is far more robust 5.
Consider repeat dosing: If FEV1 or PEF remains <40% predicted after the initial dose and 1 hour of continued intensive treatment, a repeat dose of 2 grams IV over 20 minutes may be appropriate 3.
When to Escalate Beyond Magnesium
Transfer to ICU if any of the following develop despite magnesium and maximal therapy: